HomeAI · summaries
Storia in 2 fonti
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Outer Bio Emerges from Stealth with Yuna, a Platform That Keeps Ex Vivo Human Skin Alive and Measurable for Four Weeks
Outer Bio Emerges from Stealth with Yuna, a Platform That Keeps Ex Vivo Human Skin Alive and Measurable for Four WeeksLiving, full-thickness human skin, that stays viable outside…
- ·
biopharmadive.com
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.